CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0043-1763251
Original Article

A Questionnaire Survey of Current Practice in the Management of Internal Mammary Lymph Nodes in Breast Cancer

Smitha S. Rao
1   Breast Disease Management Group, Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Nita S. Nair
1   Breast Disease Management Group, Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Tabassum Wadasadawala
2   Breast Disease Management Group, Department of Radiation Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Smruti Mokal
3   Department of Biostatistics, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
2   Breast Disease Management Group, Department of Radiation Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Rajiv Sarin
4   Cancer Genetics Unit, Breast Disease Management Group, Department of Radiation Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Vani Parmar
1   Breast Disease Management Group, Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Shalaka Joshi
1   Breast Disease Management Group, Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Rajendra A. Badwe
1   Breast Disease Management Group, Department of Surgical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations

Abstract

Zoom Image
Nita S. Nair

Background Radiotherapy (RT) is an important modality in the management of breast cancers (BC). Large randomized trials have suggested that prophylactic regional nodal irradiation inclusive of internal mammary lymph nodes (IMLN) reduces BC-related mortality. However, the adoption of IMLN-RT has been variable due to relative benefits and toxicity concerns.

Methods A survey was emailed to radiation oncologists (ROs) across the country wherein they were asked about their practice regarding IMLN-RT in BC.

Results We received 128 responses, which included radiation oncologists across both private institutions (PIs) and government institutions (GIs). Fifty-six (43.8%) routinely offer prophylactic(p) IMLN-RT and an additional 15 (11.71%) suggested they would have offered it in the absence of logistic constraints. Almost all, 121 (94.5%) radiate the IMLN in case of radiologically positive lymph nodes (LNs).

Fifty-six ROs (43.8%) offered prophylactic IMLN-RT in node-negative disease. Among those who did not offer IMLN-RT, most (84.72%) felt the clinical evidence was equivocal. Of the 56 who offered pIMLN-RT, 34/56 (60.71%) offered to locally advanced tumors, 20/56 (35.71%) offered to all inner and central tumors (ICQT), 29/56 (51.78%) to > 4 axillary LN-positive and 9/56 (16.07%) to any axillary LN-positive. The majority, i.e., 36/56 (64.28%) radiated upper three intercostal spaces, 9 (16.07%) radiated upper five intercostal spaces, and 6 (10.9%) decided based on tumor location, while 5 (9%) irradiated one space below the involved space.

Overall, simulation-based planning was undertaken in 99% of PIs as opposed to 89% of GIs (p = 0.03). The majority of ROs, i.e., 92 (72.4%) preferred IMRT to IMLN-RT.

In addition, the surgical approach to IMLN was practiced by surgeons at 18 (14%) centers, of which 13 (72.22%) operated the IMLN when radiologically evident. The IMLN dissection was preferentially performed for second and third intercostal spaces as suggested in 10 (55.55%) responses, while 8 (44.44%) performed thoracoscopic dissection of the IMLN chain. The distribution of prophylactic, definitive IMLN-RT, and IMLN dissection did not differ significantly between GI and PI (p = NS).

Conclusions pIMLN-RT is still not the standard protocol in most centers citing equivocal evidence in the literature. Logistics, though different in GIs and PIs, did not impact the decision of pIMLN-RT. Further efforts would be required to standardize practice in IMLN across India.

Disclaimer

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.




Publication History

Article published online:
09 March 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72 (01) 7-33 DOI: 10.3322/caac.21708.
  • 2 Poortmans PM, Collette S, Kirkove C. et al; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373 (04) 317-327
  • 3 Poortmans PM, Weltens C, Fortpied C. et al; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol 2020; 21 (12) 1602-1610 DOI: 10.1016/S1470-2045(20)30472-1.
  • 4 Thorsen LB, Offersen BV, Danø H. et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol 2016; 34 (04) 314-320
  • 5 Dodwell D, Taylor C, McGale P. et al. Regional lymph node irradiation in early stage breast cancer: an EBCTCG meta-analysis of 13,000 women in 14 trials. 2018 San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 4–8, 2018 Abstract GS4–02
  • 6 Budach W, Bölke E, Kammers K, Gerber PA, Nestle-Krämling C, Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiat Oncol 2015; 10: 258
  • 7 Leite ETT, Ugino RT, Santana MA. et al. Incidental irradiation of internal mammary lymph nodes in breast cancer: conventional two-dimensional radiotherapy versus conformal three-dimensional radiotherapy. Radiol Bras 2016; 49 (03) 170-175
  • 8 Kim YB, Byun HK, Kim DY. et al. Effect of elective internal mammary node irradiation on disease-free survival in women with node-positive breast cancer: a randomized phase 3 clinical trial. JAMA Oncol 2022; 8 (01) 96-105
  • 9 Wadasadawala T, Bajpai J. Internal mammary nodal irradiation: the jury is still out!. Clin Oncol 2016; 1 (01) 1-3 , article 1119
  • 10 Roumeliotis M, Long K, Phan T, Graham D, Quirk S. Including internal mammary lymph nodes in radiation therapy for synchronous bilateral breast cancer: an international survey of treatment technique and clinical priorities. Breast Cancer Res Treat 2018; 171 (02) 471-475
  • 11 Hennequin C, Bossard N, Servagi-Vernat S. et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys 2013; 86 (05) 860-866
  • 12 National Comprehensive Cancer Network. Breast Cancer (Version 3.2022). Accessed June 06, 2022, at: http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
  • 13 Whelan TJ, Olivotto IA, Parulekar WR. et al; MA.20 Study Investigators. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015; 373 (04) 307-316
  • 14 Taghian A, Jagsi R, Makris A. et al. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol Phys 2004; 60 (03) 706-714
  • 15 Sachdev S, Goodman CR, Neuschler E. et al. Radiotherapy of MRI-detected involved internal mammary lymph nodes in breast cancer. Radiat Oncol 2017; 12 (01) 199
  • 16 Jia S, Liu Z, Zhang J. et al. Can internal mammary lymph nodes irradiation bring survival benefits for breast cancer patients? A systematic review and meta-analysis of 12,705 patients in 12 studies. Radiat Oncol 2021; 16 (01) 42
  • 17 Samreen N, Dhage S, Gerber NK, Chacko C, Lee CS. Imaging and management of internal mammary lymph nodes. J Breast Imaging 2020; 2 (06) 530-540
  • 18 Chen L, Gu Y, Leaw S. et al. Internal mammary lymph node recurrence: rare but characteristic metastasis site in breast cancer. BMC Cancer 2010; 10: 479
  • 19 Duma MN. An update on regional nodal irradiation: indication, target volume delineation, and radiotherapy techniques. Breast Care (Basel) 2020; 15 (02) 128-135
  • 20 Cong BB, Cao XS, Cao L. et al. Internal mammary lymph nodes radiotherapy of breast cancer in the era of individualized medicine. Oncotarget 2017; 8 (46) 81583-81590
  • 21 Zhou ZR, Yang ZZ, Yu XL, Guo XM. Is internal mammary nodes irradiation as a part of breast cancer postoperative radiotherapy necessary?. J Thorac Dis 2016; 8 (11) 3427-3430
  • 22 Caudle AS, Smith BD. Do internal mammary nodes matter?. Ann Surg Oncol 2019; 26 (04) 930-932
  • 23 Urban JA, Marjani MA. Significance of internal mammary lymph node metastases in breast cancer. Am J Roentgenol Radium Ther Nucl Med 1971; 111 (01) 130-136
  • 24 Morimoto T, Monden Y, Takashima S. et al. Five-year results of a randomized clinical trial comparing modified radical mastectomy and extended radical mastectomy for stage II breast cancer. Surg Today 1994; 24 (03) 210-214
  • 25 Lacour J, Lê MG, Hill C, Kramar A, Contesso G, Sarrazin D. Is it useful to remove internal mammary nodes in operable breast cancer?. Eur J Surg Oncol 1987; 13 (04) 309-314
  • 26 Veronesi U, Marubini E, Mariani L, Valagussa P, Zucali R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer 1999; 35 (09) 1320-1325 DOI: 10.1016/s0959-8049(99)00133-1.
  • 27 Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol 2008; 26 (30) 4981-4989 DOI: 10.1200/JCO.2008.17.4862.
  • 28 Haffty BG, Whelan T, Poortmans PM. Radiation of the Internal Mammary Nodes: Is There a Benefit?. J Clin Oncol 2016; 34 (04) 297-299
  • 29 Wang K, Zhang X, Zheng K. et al. Predictors of internal mammary lymph nodes (IMLN) metastasis and disease-free survival comparison between IMLN-positive and IMLN-negative breast cancer patients: Results from Western China Clinical Cooperation Group (WCCCG) database (CONSORT). Medicine (Baltimore) 2018; 97 (28) e11296
  • 30 Belkacemi Y, Kaidar-Person O, Poortmans P. et al; Breast Working Party of the EORTC Radiation Oncology Group (ROG). Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey. Ann Oncol 2015; 26 (03) 529-535